Resultados de la búsqueda 121-130 of 15511 for LL-37
This phase II trials studies how well acalabrutinib with or without obinutuzumab works in treating participants with early-stage chronic lymphocytic leukemia or ...
... 2 or 3 meningioma as measured by 6-month PFS rate. Intraoperative Contrast Enhanced Ultrasound for the Identification of Pituitary Adenoma in Cushing's ...
... II). Additinoally, to evaluate the effectiveness ... 2 Dose (RP2D) in patients with HCC and ICC ... Ir a página 3737 · Ir a página 3838 · Ir a página 39 ...
Venetoclax may stop the growth of cancer cells by blocking Bcl-2, a protein needed for cancer cell survival. Giving venetoclax with ibrutinib and rituximab with ...
... II dose (RP2D of APG2575 in combination with Pomalidomide/dexamethasone (Pd) in patients with relapsed/refractory (R/R) multiple myeloma (MM), or ...
The hypothesis is that the early surgery group will have a significantly lower all-cause mortality and incidence of acute aortic events at 2 years of follow up ...
For cycles 2-6: patient will visit the clinic once every 2 weeks for checkups and tests. Remain in long term follow-up for a period of four additional years ...
All study subjects will receive acalabrutinib, durvalumab, and venetoclax. Acalabrutinib is FDA approved for treatment of chronic lymphocytic leukemia and small ...
Mayo Clinic no respalda compañías ni productos. Las recaudaciones de los avisos comerciales financian nuestra misión sin fines de lucro.
Consulta estos éxitos de venta y ofertas especiales en libros y boletines informativos de Mayo Clinic Press.
¿Te gustaría hacer una donación deducible de impuestos y ser parte de una investigación de vanguardia y de una atención médica que transforma la medicina?